CEL-SCI To Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
February 08 2016 - 9:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) announced today that
Geert Kersten, Chief Executive officer, will provide a company
overview at the Source Capital Group’s 2016 Disruptive Growth &
Healthcare Conference on Wednesday, February 10, 2016 at 1:00 p.m.
in New York City. For more information on the conference or for
investors to register, please go to
www.SourceCapitalConference.com.
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief
that the best investment advice should be independent, unbiased and
tailor-made for the individual client’s needs. Source Capital began
as a boutique investment banking firm specializing in small to
medium sized transactions. We have grown to include businesses in
general securities, emerging market securities, distressed and high
yield debt securities, in addition to our investment banking
activity. http://www.sourcegrp.com/
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform
technologies that can potentially treat a variety of cancers and
viral diseases. We believe that one must activate the immune system
BEFORE radiation and chemotherapy, and even before surgery, to
achieve the best results in the greatest number of patients.
CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine
(Leukocyte Interleukin Injection) for the treatment of head and
neck cancer, which accounts for about 6% of cancers globally and a
$6 billion market. Almost 700 patients are already enrolled in this
study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV
infected patients with HPV related diseases. CEL-SCI has
development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its
own 75,000 sq. ft. manufacturing facility and produces Multikine
for its clinical trials. When fully built out, this facility will
have the capacity to supply about $3 billion worth of Multikine
annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S.
(Ligand Epitope Antigen Presentation System) technology as a
potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208005589/en/
COMPANY CONTACT:CEL-SCI CorporationGavin de Windt,
703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024